NCCN Clinical Practice Guidelines in Oncology Pancreatic Adenocarcinoma, version 1.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed 24 Feb 2023.

Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–22.

Article  PubMed  Google Scholar 

Takahashi H, Ohigashi H, Gotoh K, et al. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013;258(6):1040–50.

Article  PubMed  Google Scholar 

Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220–30.

Article  CAS  PubMed  Google Scholar 

Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 Phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9):1263–70.

Article  PubMed  PubMed Central  Google Scholar 

Tomihara H, Yamada D, Eguchi H, et al. MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Cancer Sci. 2017;108(3):398–407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264(3):457–63.

Article  PubMed  Google Scholar 

Lutfi W, Talamonti MS, Kantor O, et al. Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. Am J Surg. 2017;213(3):521–5.

Article  PubMed  Google Scholar 

Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–48.

Article  PubMed  Google Scholar 

Jan IS, Ch’ang HJ. Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy. Radiat Oncol. 2023;18(1):137.

Article  PubMed  PubMed Central  Google Scholar 

Nishiwada S, Sho M, Cui Y, et al. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Int J Cancer. 2021;148(3):769–79.

Article  CAS  PubMed  Google Scholar 

Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011;29(22):3037–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whittle MC, Izeradjene K, Rani PG, et al. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Cell. 2015;161(6):1345–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kitano M, Yoshida T, Itonaga M, Tamura T, Hatamaru K, Yamashita Y. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. J Gastroenterol. 2019;54(1):19–32.

Article  PubMed  Google Scholar 

Baek HW, Park MJ, Rhee YY, Lee KB, Kim MA, Park IA. Diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology of pancreatic lesions. J Pathol Transl Med. 2015;49(1):52–60.

Article  PubMed  PubMed Central  Google Scholar 

Luchini C, Veronese N, Nottegar A, et al. Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: a meta-analysis towards precision medicine. Cancers (Basel). 2019;11(8):1152.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou J, Li X, Xie KP. Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. Mol Cancer. 2021;20(1):34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perales S, Torres C, Jimenez-Luna C, et al. Liquid biopsy approach to pancreatic cancer. World J Gastrointest Oncol. 2021;13(10):1263–87.

Article  PubMed  PubMed Central  Google Scholar 

Sun Z, Shi K, Yang S, et al. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17(1):147.

Article  PubMed  PubMed Central  Google Scholar 

Tomimaru Y, Eguchi H, Nagano H, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer. 2010;103(10):1617–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iwagami Y, Eguchi H, Nagano H, et al. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer. 2013;109(2):502–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H, Liu J, Chen J, et al. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nat Commun. 2018;9(1):1614.

Article  PubMed  PubMed Central  Google Scholar 

Vannini I, Rossi T, Melloni M, et al. Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value. Mol Ther Methods Clin Dev. 2023;29:473–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei F, Liu Y, Guo Y, et al. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Mol Cancer. 2013;12(81).

Wang P, Zhang J, Zhang L, et al. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology. 2013;145(5):1133-1143 e1112.

Article  CAS  PubMed  Google Scholar 

Tan L, Chen Z. miR-193a-5p enhances the radioresistance of pancreatic cancer cells by targeting ZFP57 and activating the Wnt pathway. J Oncol. 2022;2022:8071343.

Article  PubMed  PubMed Central  Google Scholar 

Wei H, Wen-Ming C, Jun-Bo J. Plasma miR-145 as a novel biomarker for the diagnosis and radiosensitivity prediction of human cervical cancer. J Int Med Res. 2017;45(3):1054–60.

Article  PubMed  PubMed Central  Google Scholar 

Ono Y, Inoue Y, Ito H, et al. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels. HPB (Oxford). 2023;25(1):100–8.

Article  PubMed  Google Scholar 

Tsai S, George B, Wittmann D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg. 2020;271(4):740–7.

Article  PubMed  Google Scholar 

Takahashi H, Akita H, Ioka T, et al. Phase I trial evaluating the safety of preoperative gemcitabine/nab-paclitaxel with concurrent radiation therapy for borderline resectable pancreatic cancer. Pancreas. 2018;47(9):1135–41.

Article  CAS  PubMed  Google Scholar 

Eguchi H, Takeda Y, Takahashi H, et al. A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 Concurrent with radiation for resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019;26(13):4498–505.

Article  PubMed  Google Scholar 

Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335–9.